Accéder au contenu
Merck

[Effectiveness of eradication anti-helicobacter therapy in patients with duodenal ulcer in different drug dosage regimens].

Klinicheskaia meditsina (2003-07-24)
Z M Orziev, F E Nurbaev, G Sh Rakhimova
RÉSUMÉ

46 patients having exacerbation of duodenal ulcer in the presence of Helicobacter pylori (HP) were studied for efficacy of HP eradication treatment which comprised omeprazole (40 mg/day), colloid bismuth subcitrate (480 mg/day) and metronidazole (1000 mg/day) for 2 weeks. According to the dosage regimen the patients were divided into two groups. Patients of group 1 received the drugs in fractions, of group 2--in a single daily doses. The eradication therapy in both dosage regimen was high (73 and 88%, respectively). Thus, it is proved that single daily doses of actibacterial drugs can be also used in clinical practice for conduction of eradication therapy.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Bismuth(III) subnitrate, 98%
Sigma-Aldrich
Bismuth subnitrate, meets USP testing specifications